Boston Scientific Corp. stock climbed nearly 4% in mid-day trading following the disclosure of two major corporate moves announced together: a $2 billion accelerated share repurchase (ASR) agreement and a $1.5 billion strategic equity investment in privately held MiRus LLC.
The ASR was executed with JPMorgan Chase Bank and is part of Boston Scientific's previously disclosed $5 billion share repurchase authorization. Under the agreement's terms, Boston Scientific will receive common shares representing roughly 30.4 million shares, calculated using the May 15, 2026 closing price of $52.68.
In parallel, Boston Scientific said it invested $1.5 billion to acquire about a 34% ownership stake in MiRus LLC. The deal also provides Boston Scientific with an exclusive option to acquire MiRus's balloon-expandable Transcatheter Aortic Valve Replacement system, subject to additional payments and completion of milestones set by the parties.
The technology at the center of the MiRus arrangement is branded SIEGEL and is described as being built on a proprietary rhenium alloy. The company characterizes the valve as the first nickel-free, balloon-expandable TAVR device intended to restore function and normal blood flow in severely narrowed aortic valves.
Analysts noted the transaction as Boston Scientific's third attempt to enter the TAVR segment. Truist Securities reaffirmed its Buy rating and maintained an $85.00 price target on Boston Scientific following the announcements. On the financial side, the company expects the $2 billion ASR to contribute approximately $0.02 to adjusted earnings per share for the full year 2026, a figure the company says is accretive to previously issued guidance.
Market context underlines that the move was company-driven. Major U.S. indexes were not providing a lift to shares: the S&P 500 slipped -0.30% to 7,386.01, the Dow Jones Industrial Average was essentially flat at -0.01%, and the NASDAQ fell -0.69% to 26,045.28. That performance indicates Boston Scientific's advance was tied to its own announcements rather than broader market strength.
The $1.5 billion MiRus investment secures the roughly 34% equity position and the exclusive option on MiRus's TAVR business, a segment the company and analysts view as addressing a global TAVR market estimated at $7 billion. Boston Scientific described the pairing of the shareholder-friendly ASR and the strategic TAVR investment as offering investors both near-term and longer-term reasons to support the stock.
Commenting on the move, Lance Bates, executive vice president and president of Interventional Cardiology and Vascular Therapies at Boston Scientific, said: "The occurrence and recognition of aortic stenosis is growing rapidly and our investment in MiRus continues our pursuit to bring a differentiated TAVR system into our portfolio."
Taken together, the accelerated repurchase and the MiRus transaction provided immediate earnings accretion and a path to expand Boston Scientific's interventional cardiology offerings, reinforcing investor interest in the shares despite a lack of positive direction from major indexes.
Additional context provided by the company: the ASR is executed under the existing $5 billion repurchase authorization and the MiRus arrangement is structured with milestone-dependent additional payments in order to exercise the exclusive option to acquire the balloon-expandable TAVR system.